Otto Simonsson

Researcher in Clinical Neuroscience at Karolinska Institute

Data updated

Papers

22 publications

Trials

0 clinical trials

Research Footprint

Otto Simonsson appears in 22 tracked papers (2021–2026), most studied alongside Psilocybin, Ayahuasca and DMT, across Substance Use Disorders (SUD), Depressive Disorders and Anxiety Disorders.

Most-cited paper: Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics (124 citations).

Frequent co-authors: Peter Hendricks, Wojciech Osika and Samuel Goldberg.

Background & Research

Otto Simonsson is a Swedish researcher whose work examines the prevalence of mental health outcomes associated with naturalistic psychedelic use. He investigates how individual factors, such as a family history of mental illness, influence the response to psychedelics. His research aims to provide a more nuanced understanding of safety and risk profiles for psychedelic medicine in diverse populations.

Key Impact

Explores the psychiatric risks and benefits of psychedelic use, focusing on genetic and environmental factors.

22

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

41 collaborators· click a node to visit their profile

Full network →

Compounds

PsilocybinAyahuascaDMTLSDMescalineMDMAPlacebo5-MeO-DMT

Topics

Substance Use Disorders (SUD)Depressive DisordersAnxiety DisordersImmunology & InflammationSafety & Risk ManagementAdolescentsOlder AdultsInterpersonal Functioning & Social ConnectednessPersonality & Trait FactorsBipolar DisorderSchizophreniaTobacco/Nicotine Use Disorder (TUD)Set & SettingPublic Health, Prevention & Behaviour ChangeNeuroimaging & Brain MeasuresTreatment-Resistant Depression (TRD)Implementation & Service DeliverySuicidalityPTSDPalliative & End-of-Life DistressNeurocognitive Disorders

Top Collaborators

Affiliations

Institutions, companies, and organisations Otto Simonsson is associated with.

Karolinska Institutet

Karolinska Institutet is Sweden's largest medical university and a leading European hub for psychedelic research, with the Centre for Psychiatry Research led by Prof. Johan Lundberg conducting PSIPET — Sweden's first RCT of psilocybin for major depressive disorder. The institute participates in the Nordic Network for Psychedelic Science and launched a doctoral course in psychedelic science in 2025.

View stakeholder →